The World Health Organization (WHO) recommends that countries introducing new drugs and treatment regimens for multidrug-resistant tuberculosis (MDR-TB) should develop and implement a system for active pharmacovigilance (PV) allowing for detection, reporting, and management of adverse drug reactions (ADRs).
In 2020, the TB CARE II project conducted a workshop on ‘Integrating an Electronic Pharmacovigilance Monitoring System (PViMS) Tool into National Active TB Drugs Safety Monitoring Systems (aDSM)’ in Johannesburg, South Africa. The workshop was organized as a response to countries’ requests to USAID for a capacity development towards introducing the PViMS Tool. To build the capacity of participating countries to integrate an electronic PViMS tool into existing aDSM, the workshop employed facilitatory country team discussions, experiential learning, peer learning approach, and practical sessions on the usage of the PViMS electronic tool. During the workshop, countries developed roadmaps and identified practical and country–specific approaches towards integrating PViMS tools into existing aDSM/PV systems in their countries. The workshop helped participants develop a technical understanding of web-based PViMS tool and achieve consensus on the role of PViMS in reporting adverse drug reactions, including SAEs at different levels of national PV systems.